NICE | The National Institute for Health and Care Excellence

This review considers particular challenges associated with the increase in technologies being developed for rare diseases being considered for the HST programme, challenges in the criteria interpretation and the changing disease therapies landscape for the latest health technology innovations (such as advanced therapy medicinal products (ATMP ... ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download